Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.35 |
| ▸ | PDE6D | O43924 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | IL1B | P01584 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.30 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4773538 | 0.85 | DDB1 (0.33) | CRBNDDB1 | |
| SCHEMBL4773163 | 0.82 | CRBN (0.36) | CRBNPDE6DSTAT3DDB1HPGDS | |
| SCHEMBL6817127 | 0.81 | DDB1 (0.32) | CRBNDDB1 | |
| SCHEMBL6816440 | 0.81 | CRBN (0.35) | CRBNSTAT3DDB1HPGDSTNF | |
| SCHEMBL4779018 | 0.80 | DDB1 (0.31) | CRBNDDB1 | |
| SCHEMBL4776620 | 0.79 | CRBN (0.37) | CRBNDDB1 | |
| SCHEMBL4773155 | 0.78 | CRBN (0.56) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL4780819 | 0.77 | CRBN (0.41) | CRBNDDB1IKZF3 | |
| SCHEMBL634077 | 0.77 | CRBN (0.46) | CRBNDDB1TNFIL1BIKZF1 | |
| SCHEMBL12041891 | 0.76 | DDB1 (0.49) | CRBNPDE6DSTAT3DDB1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524742-B2 | Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-09-03 | — | — | US | disclosed |
| US-8524742-B2 | Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-09-03 | — | — | US | disclosed |
| US-8524742-B2 | Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-09-03 | — | — | US | disclosed |
| EP-1964842-B1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | TIAN JIN HEMAY BIO TECH CO LTD (CN) | 2012-09-12 | — | — | EP | disclosed |
| EP-1964842-B1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | TIAN JIN HEMAY BIO TECH CO LTD (CN) | 2012-09-12 | — | — | EP | disclosed |
| US-20120220631-A1 | USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-20120220631-A1 | USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-20120220631-A1 | USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-8183260-B2 | small molecule, low toxicity, high efficiency, high economic value; 5-(2,6-dioxopiperidin-3-yl)-5H-thieno(3,4-c)pyrrole-4,6-dione: | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2012-05-22 | — | — | US | disclosed |
| US-8183260-B2 | small molecule, low toxicity, high efficiency, high economic value; 5-(2,6-dioxopiperidin-3-yl)-5H-thieno(3,4-c)pyrrole-4,6-dione: | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2012-05-22 | — | — | US | disclosed |
| US-8183260-B2 | small molecule, low toxicity, high efficiency, high economic value; 5-(2,6-dioxopiperidin-3-yl)-5H-thieno(3,4-c)pyrrole-4,6-dione: | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2012-05-22 | — | — | US | disclosed |
| EP-1964842-A1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964842-A1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2008-09-03 | — | — | EP | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220631-A1 | USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR | TNF, TPMT, TNFRSF1A | CRBN 1305/4885PDE6D 2382/4885STAT3 1585/4885 |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, CD40 | CRBN 938/4885PDE6D 1737/4885STAT3 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.